Revolution Medicines, Inc. (RVMD): Total Assets
$2.35B
As of 2025-12-31
$4.32B
As of 2026-06-30
+42.6%
3-year compound annual growth
+32.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.35B | -8.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $2.56B | +24.1% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $2.06B | +153.9% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $811.93M | +10.0% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $737.99M | +30.1% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $567.40M | +157.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $220.53M | n/a | 2021-03-02, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $2.35B | -8.0% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
Compare RVMD, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗